 |
 |
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
3 September 2002 | Volume 137 Issue 5 Part 2 | Pages 381-433
Summary: The availability of an increasing number of antiretroviral agents and the rapid evolution of new information have introduced substantial complexity into treatment regimens for persons infected with human immunodeficiency virus (HIV). In 1996, the Department of Health and Human Services and the Henry J. Kaiser Family Foundation convened the Panel on Clinical Practices for the Treatment of HIV to develop guidelines for clinical management of HIV-infected adults and adolescents (CDC. Report of the NIH Panel To Define Principles of Therapy of HIV Infection and Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. MMWR. 1998; 47[RR-5]:1-41]. This report, which updates the 1998 guidelines, addresses 1) using testing for plasma HIV ribonucleic acid levels [i.e., viral load] and CD4+ T cell count; 2) using testing for antiretroviral drug resistance; 3) considerations for when to initiate therapy; 4) adherence to antiretroviral therapy; 5) considerations for therapy among patients with advanced disease; 6) therapy-related adverse events; 7) interruption of therapy; 8) considerations for changing therapy and available therapeutic options; 9) treatment for acute HIV infection; 10) considerations for antiretroviral therapy among adolescents; 11] considerations for antiretroviral therapy among pregnant women; and 12) concerns related to transmission of HIV to others.
Summary: Antiretroviral regimens are complex, have serious side effects, pose difficulty with adherence, and carry serious potential consequences from the development of viral resistance because of nonadherence to the drug regimen or suboptimal levels of antiretroviral agents. Patient education and involvement in therapeutic decisions are critical. Treatment should usually be offered to all patients with symptoms ascribed to HIV infection. Recommendations for offering antiretroviral therapy among asymptomatic patients require analysis of real and potential risks and benefits. In general, treatment should be offered to persons who have <350 CD4+ T cells/mm3 or plasma HIV ribonucleic acid (RNA) levels of >55,000 copies/mL (by b-deoxyribonucleic acid [bDNA] or reverse transcriptase-polymerase chain reaction [RT-PCR] assays). The recommendation to treat asymptomatic patients should be based on the willingness and readiness of the person to begin therapy; the degree of existing immunodeficiency as determined by the CD4+ T cell count; the risk for disease progression as determined by the CD4+ T cell count and level of plasma HIV RNA; the potential benefits and risks of initiating therapy in an asymptomatic person; and the likelihood, after counseling and education, of adherence to the prescribed treatment regimen.
Summary: Treatment goals should be maximal and durable suppression of viral load, restoration and preservation of immunologic function, improvement of quality of life, and reduction of HIV-related morbidity and mortality. Results of therapy are evaluated through plasma HIV RNA levels, which are expected to indicate a 1.0 log 10 decrease at 2–8 weeks and no detectable virus (<50 copies/mL) at 4–6 months after treatment initiation. Failure of therapy at 4–6 months might be ascribed to nonadherence, inadequate potency of drugs or suboptimal levels of antiretroviral agents, viral resistance, and other factors that are poorly understood. Patients whose therapy fails in spite of a high level of adherence to the regimen should have their regimen changed; this change should be guided by a thorough drug treatment history and the results of drug-resistance testing. Because of limitations in the available alternative antiretroviral regimens that have documented efficacy, optimal changes in therapy might be difficult to achieve for patients in whom the preferred regimen has failed. These decisions are further confounded by problems with adherence, toxicity, and resistance. For certain patients, participating in a clinical trial with or without access to new drugs or using a regimen that might not achieve complete suppression of viral replication might be preferable. Because concepts regarding HIV management are evolving rapidly, readers should check regularly for additional information and updates at the HIV/AIDS Treatment Information Service website ( http://www.hivatis.org ).
Author and Article Information
This document was originally published in MMWR on 14 June 2002 (RR81).
GUIDELINES FOR USING ANTIRETROVIRAL AGENTS AND PREVENTING OPPORTUNISTIC INFECTIONS AMONG HIV-INFECTED PERSONS
Guidelines for Using Antiretroviral Agents among HIV-Infected Adults and Adolescents: The Panel on Clinical Practices for Treatment of HIV*
This article has been cited by other articles:
|
|
 |
|
  A. W. Carrico and M. H. Antoni Effects of Psychological Interventions on Neuroendocrine Hormone Regulation and Immune Status in HIV-Positive Persons: A Review of Randomized Controlled Trials Psychosom Med, June 1, 2008; 70(5): 575 - 584. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. S. Zaric, A. M. Bayoumi, M. L. Brandeau, and D. K. Owens The Cost-Effectiveness of Counseling Strategies to Improve Adherence to Highly Active Antiretroviral Therapy among Men Who Have Sex with Men Med Decis Making, June 1, 2008; 28(3): 359 - 376. [Abstract] [PDF]
|
|
|
|
 |
|
 I. B Wilson, B. E Landon, P. V Marsden, L. R Hirschhorn, K. McInnes, L. Ding, and P. D Cleary Correlations among measures of quality in HIV care in the United States: cross sectional study BMJ, November 24, 2007; 335(7629): 1085 - 1085. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. F. Marier, M. DiMarco, R. Guilbaud, C. Dodard, G. Morelli, S. K. Tippabhotla, A. K. Singla, N. R. Thudi, and T. Monif Pharmacokinetics of Lamivudine, Zidovudine, and Nevirapine Administered as a Fixed-Dose Combination Formulation Versus Coadministration of the Individual Products J. Clin. Pharmacol., November 1, 2007; 47(11): 1381 - 1389. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. B. Nachega, M. Hislop, D. W. Dowdy, R. E. Chaisson, L. Regensberg, and G. Maartens Adherence to Nonnucleoside Reverse Transcriptase Inhibitor Based HIV Therapy and Virologic Outcomes Ann Intern Med, April 17, 2007; 146(8): 564 - 573. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Pan, J. Kim, L. Chen, Q. Wang, and C. Lee The HIV positive selection mutation database Nucleic Acids Res., January 12, 2007; 35(suppl_1): D371 - D375. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Teerawattananon, W. Hanshaoworakul, S. Russell, V. Tangcharoensathien, and S. Jiamton Targeting Antiretroviral Therapy: Lessons from a Longitudinal Study of Morbidity and Treatment in Relation to CD4 Count in Thailand Asia Pac J Public Health, March 1, 2006; 18(1): 39 - 48. [PDF]
|
|
|
|
 |
|
 Z. Gu, B. Allard, J. M. de Muys, J. Lippens, R. F. Rando, N. Nguyen-Ba, C. Ren, P. McKenna, D. L. Taylor, and R. C. Bethell In Vitro Antiretroviral Activity and In Vitro Toxicity Profile of SPD754, a New Deoxycytidine Nucleoside Reverse Transcriptase Inhibitor for Treatment of Human Immunodeficiency Virus Infection Antimicrob. Agents Chemother., February 1, 2006; 50(2): 625 - 631. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. H. Antoni, A. W. Carrico, R. E. Duran, S. Spitzer, F. Penedo, G. Ironson, M. A. Fletcher, N. Klimas, and N. Schneiderman Randomized Clinical Trial of Cognitive Behavioral Stress Management on Human Immunodeficiency Virus Viral Load in Gay Men Treated With Highly Active Antiretroviral Therapy Psychosom Med, January 1, 2006; 68(1): 143 - 151. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Error in Renumbering References in Text and Reference List in: Antiretroviral Therapy and the Prevalence and Incidence of Diabetes Mellitus in the Multicenter AIDS Cohort Study Arch Intern Med, November 28, 2005; 165(21): 2541 - 2541. [Full Text] [PDF]
|
|
|
|
 |
|
 D. V. Nissley, E. K. Halvas, N. L. Hoppman, D. J. Garfinkel, J. W. Mellors, and J. N. Strathern Sensitive Phenotypic Detection of Minor Drug-Resistant Human Immunodeficiency Virus Type 1 Reverse Transcriptase Variants J. Clin. Microbiol., November 1, 2005; 43(11): 5696 - 5704. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Coco The Cost-Effectiveness of Expanded Testing for Primary HIV Infection Ann. Fam. Med, September 1, 2005; 3(5): 391 - 399. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. T. Brown, S. R. Cole, X. Li, L. A. Kingsley, F. J. Palella, S. A. Riddler, B. R. Visscher, J. B. Margolick, and A. S. Dobs Antiretroviral Therapy and the Prevalence and Incidence of Diabetes Mellitus in the Multicenter AIDS Cohort Study Arch Intern Med, May 23, 2005; 165(10): 1179 - 1184. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. M. Lampinen, K. Chan, R. S. Remis, M. F. Merid, M. Rusch, J. Vincelette, K. Logue, V. Popovic, M. Alary, M. T. Schechter, et al. Sexual risk behaviour of Canadian participants in the first efficacy trial of a preventive HIV-1 vaccine Can. Med. Assoc. J., February 15, 2005; 172(4): 479 - 483. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Bussmann, C. W. Wester, K. V. Masupu, T. Peter, S. M. Gaolekwe, S. Kim, A. M. Reich, S. Ahn, Y. Wu, I. Thior, et al. Low CD4+ T-Lymphocyte Values in Human Immunodeficiency Virus-Negative Adults in Botswana Clin. Vaccine Immunol., September 1, 2004; 11(5): 930 - 935. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. G. Deeks, C. M. R. Kitchen, L. Liu, H. Guo, R. Gascon, A. B. Narvaez, P. Hunt, J. N. Martin, J. O. Kahn, J. Levy, et al. Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load Blood, August 15, 2004; 104(4): 942 - 947. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Olatinwo, R. G. Hewitt, and R. C. Venuto Human Immunodeficiency Virus-Associated Nephropathy: A Primary Care Perspective Arch Intern Med, February 9, 2004; 164(3): 333 - 336. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Yazdanpanah, D. Sissoko, M. Egger, Y. Mouton, M. Zwahlen, and G. Chene Clinical efficacy of antiretroviral combination therapy based on protease inhibitors or non-nucleoside analogue reverse transcriptase inhibitors: indirect comparison of controlled trials BMJ, January 31, 2004; 328(7434): 249. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Montessori, N. Press, M. Harris, L. Akagi, and J. S.G. Montaner Adverse effects of antiretroviral therapy for HIV infection Can. Med. Assoc. J., January 20, 2004; 170(2): 229 - 238. [Abstract] [Full Text]
|
|
|
|
|
|
E. Wood, R. S. Hogg, B. Yip, P. R. Harrigan, M. V. O'Shaughnessy, and J. S.G. Montaner Effect of Medication Adherence on Survival of HIV-Infected Adults Who Start Highly Active Antiretroviral Therapy When the CD4+ Cell Count Is 0.200 to 0.350 x 109 cells/L Ann Intern Med, November 18, 2003; 139(10): 810 - 816. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Bogaards and J. Goudsmit Meeting the immense need for HAART in resource-poor settings J. Antimicrob. Chemother., November 1, 2003; 52(5): 743 - 746. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Heredia, A. Amoroso, C. Davis, N. Le, E. Reardon, J. K. Dominique, E. Klingebiel, R. C. Gallo, and R. R. Redfield Rapamycin causes down-regulation of CCR5 and accumulation of anti-HIV {beta}-chemokines: An approach to suppress R5 strains of HIV-1 PNAS, September 2, 2003; 100(18): 10411 - 10416. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. I. Abrams, J. F. Hilton, R. J. Leiser, S. B. Shade, T. A. Elbeik, F. T. Aweeka, N. L. Benowitz, B. M. Bredt, B. Kosel, J. A. Aberg, et al. Short-Term Effects of Cannabinoids in Patients with HIV-1 Infection: A Randomized, Placebo-Controlled Clinical Trial Ann Intern Med, August 19, 2003; 139(4): 258 - 266. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. L. Kimmel, L. Barisoni, and J. B. Kopp Pathogenesis and Treatment of HIV-Associated Renal Diseases: Lessons from Clinical and Animal Studies, Molecular Pathologic Correlations, and Genetic Investigations Ann Intern Med, August 5, 2003; 139(3): 214 - 226. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. J. Palella Jr., M. Deloria-Knoll, J. S. Chmiel, A. C. Moorman, K. C. Wood, A. E. Greenberg, S. D. Holmberg, and the HIV Outpatient Study (HOPS) Investigators* Survival Benefit of Initiating Antiretroviral Therapy in HIV-Infected Persons in Different CD4+ Cell Strata Ann Intern Med, April 15, 2003; 138(8): 620 - 626. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. C. Lane and J. D. Neaton When To Start Therapy for HIV Infection: A Swinging Pendulum in Search of Data Ann Intern Med, April 15, 2003; 138(8): 680 - 681. [Full Text] [PDF]
|
|
|
|
 |
|
 P. A. Volberding, K. R. Baker, and A. M. Levine Human Immunodeficiency Virus Hematology Hematology, January 1, 2003; 2003(1): 294 - 313. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Correction: Guidelines for Using Antiretroviral Agents among HIV-Infected Adults and Adolescents Ann Intern Med, November 5, 2002; 137(9): 778 - 778. [Full Text] [PDF]
|
|
|
|
 |
|
 New HIV Guidelines Pull Back on Antiretroviral Drugs Journal Watch (General), September 24, 2002; 2002(924): 1 - 1. [Full Text]
|
|
Article
